Risk of colorectal cancer and cancer-related mortality in type 2 diabetes patients treated with metformin, SGLT-2 inhibitors, or their combination.

Cancer Commun (Lond) · 2025 · PMC12328085 · PMID 40275591

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

of borderline significanceno p-value reported

For right‐sided CRC, the association was of borderline significance with respect to SGLT‐2i/metformin (HR, 0.63; 95% CI, 0.40‐1.01) while SGLT‐2i had no beneficial effect (HR, 0.34; 95% CI, 0.10‐1.13).

also in 2,624 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.